Catalyst Pharmaceuticals, Inc.'s plan to expand Firdapse (amifampridine phosphate) to a broader range of inherited neuromuscular disorders has stalled for a second time with a Phase III clinical trial failure in patients with anti-MuSK antibody-positive myasthenia gravis, following a failed clinical trial in another rare neuromuscular condition last year.
The company announced the latest study failure with its second quarter financial results on 11 August
Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
